- ·The complete investor list: 13 names
- ·Watch Ascend (Drug Discovery): the Monday email on marks, rounds and moves
Ascend (Drug Discovery) funding history
No funding rounds for Ascend (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ascend (Drug Discovery) valuation
Ascend (Drug Discovery)'s last known valuation is $151 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How Ascend (Drug Discovery)'s valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Ascend (Drug Discovery), too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked about Ascend (Drug Discovery)
- What is Ascend (Drug Discovery) worth?
- Ascend (Drug Discovery)'s last known valuation is $150.9M.
- How much has Ascend (Drug Discovery) raised?
- Ascend (Drug Discovery) has raised $194.3M in total funding across its recorded rounds.